Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib

A case report

Masayo Yamamoto, MD, PhD, a Katsuya Ikuta, MD, PhD, a, 1 Yasumichi Toki, MD, PhD, a, 1 Mayumi Hatayama, MD, PhD, a Motohiro Shindo, MD, PhD, a Yoshihiro Torimoto, MD, PhD, b Toshikatsu Okumura, MD, PhD

Abstract

Rationale: Hypereosinophilic syndrome (HES) is a rare disorder characterized by hypereosinophilia and organ damage. Some cases of HES are caused by the FIP1L1/PDGFRA fusion gene and respond to imatinib. FIP1L1/PDGFRA-positive HES occasionally evolves into chronic eosinophilic leukemia or into another form of myeloproliferative neoplasm; however, the development of a malignant lymphoma is very rare. We present a rare case of angioimmunoblastic T-cell lymphoma (AITL) and HES with the FIP1L1/PDGFRA gene rearrangement.

Patient concerns: A man in his 30s presented to our hospital with fever, hypereosinophilia, widespread lymphadenopathy, and splenomegaly. Laboratory tests showed hypereosinophilia, increased soluble interleukin-2 receptor, and increased vitamin B12. Positron-emission tomography with 18F fluorodeoxyglucose (FDG) showed positive FDG uptake in multiple enlarged lymph nodes throughout the body and the red bone marrow. A bone-marrow biopsy showed hypereosinophilia without dysplasia and an increased number of blasts. The FIP1L1/PDGFRA fusion gene was positive upon fluorescence in situ hybridization (FISH) analysis of the peripheral blood. Furthermore, biopsy of a lymph node from the neck revealed restiform hyperplasia of capillary vessels, with small lymphoma cells arranged around the capillaries. Lymphoma cells were positive for CD3, CD4, and CD10, and negative for CD20. Lymphoma cells were also positive for the FIP1L1/PDGFRA fusion gene by FISH analysis.

Diagnoses: From these findings, the patient was diagnosed with HES and AITL with FIP1L1/PDGFRA.

Interventions: After the diagnosis, corticosteroid was administered but was ineffective. Imatinib was then administered.

Outcomes: Imatinib was very effective for treating HES and AITL, and complete remission was achieved in both.

Lessons: This report presents the first case in which the FIP1L1/PDGFRA fusion gene was positive both in peripheral blood and lymph nodes, implying the possibility that the tumor cells acquired the FIP1L1/PDGFRA fusion gene in the early stage of hematopoietic progenitor cell developments. Imatinib was very effective in treating both HES and lymphoma, suggesting that the FIP1L1/PDGFRA fusion gene plays a key role in the pathogenesis of both HES and lymphoma.

Abbreviations: AITL = angioimmunoblastic T-cell lymphoma, CEL = chronic eosinophilic leukemia, CI = conflicts of interest, CR = complete remission, CT = computed tomography, FDG = 18F-fluorodeoxyglucose, FISH = fluorescence in situ hybridization, HES = hypereosinophilic syndrome, IL = interleukin, LDH = lactate dehydrogenase, MPN = myeloproliferative neoplasm, SD = standard deviation, sIL-2R = soluble interleukin-2 receptor, TCR = T-cell receptor.

Keywords: angioimmunoblastic T-cell lymphoma, FIP1L1/PDGFRA, hypereosinophilic syndrome, imatinib

1. Introduction

Hypereosinophilic syndrome (HES) encompasses a group of rare disorders characterized by the presence of marked peripheral blood eosinophilia, tissue eosinophilia, or both, resulting in organ damage attributable to the eosinophilia. 1-3 HES can be treated with steroids, hydroxyurea, and interferon-α; however, when the FIP1L1/PDGFRA fusion gene is present, imatinib is an effective treatment alternative. 1,4 HES sometimes arises in combination with chronic eosinophilic leukemia (CEL), myeloproliferative neoplasms (MPNs), and malignant lymphoma, making it a life-threatening condition. From previous reports, the FIP1L1/PDGFRA fusion gene is sometimes found in CEL or MPN with HES, but very rarely in malignant lymphoma. Here, we report a case of HES with lymphoma in which the FIP1L1/PDGFRA fusion gene was present in both diseases. Moreover, imatinib effectively treated both diseases.
2. Case report

A man in his 30s visited a local clinic because of fever and cervical lymphadenopathy. Computed tomography (CT) revealed widespread lymphadenopathy and splenomegaly. His laboratory tests showed increased lactate dehydrogenase (LDH) and soluble interleukin-2 receptor (sIL-2R) levels, and hypereosinophilia (HE), indicating a possible hematological disorder. He was then referred to our hospital. The patient had a pre-existing condition of epilepsy, for which he had been receiving sodium valproate and carbamazepine for more than 10 years without adverse effects. His family history was negative for hematological abnormalities, including HE. He had a temperature of 38.2°C, but his other vital signs were within the normal range. When he visited our hospital, several lymph nodes were palpable in his neck (the largest of which measured approximately 20mm).

A complete blood count showed leukocytosis with HE (55.0% of white blood cells), anemia, and mild thrombocytopenia. Blasts were not observed in the peripheral blood. Biochemical testing showed increased vitamin B12 and sIL-2R levels (Table 1). Tested cytokine (such as interleukin [IL]-2, IL-3, or IL-5) levels were within the normal range. The FIP1L1/PDGFRA fusion gene was positive (68%) by fluorescence in situ hybridization (FISH) analysis in the peripheral blood (Fig. 1A).

A bone-marrow biopsy was performed to test for HE. A bone-marrow biopsy showed HE (30.8% of nucleated cell counts) without dysplasia and a number of blasts was not increased (0.8% of nucleated cell counts). Furthermore, no lymphoma cells were detected in the bone marrow. No evidence of monoclonal tumor cells was found by flow cytometry analysis. A chromosomal analysis revealed a normal G-band karyotype. The T-cell receptor (TCR) gene rearrangement was negative based on Western blot analysis of the bone marrow, whereas the FIP1L1/PDGFRA fusion gene was positive in segmented nucleated cells (82%) based on FISH analysis (Fig. 2). The patient had high fever, anemia, and splenomegaly most likely from the eosinophilia; thus, he was diagnosed with FIP1L1/PDGFRA-positive HES.

In addition, a CT from the previous hospital revealed widespread lymphadenopathy and splenomegaly; thus, positron-emission tomography with 18F-fluorodeoxyglucose (FDG-PET) was performed. As shown in Figure 3A, FDG-PET showed widespread lymphadenopathy and splenomegaly.

![Figure 1](image1.png)

**Figure 1.** (A) FISH analysis of peripheral blood before imatinib treatment. The FIP1L1/PDGFRA fusion gene was positive in 86% of nucleated cells. The white arrow indicates the FIP1L1/PDGFRA fusion signal in the image of FISH. The black arrow indicates the normal signal and the red arrow indicates the FIP1L1/PDGFRA fusion signal in the illustration. (B) Six months after initiating imatinib therapy, the FIP1L1/PDGFRA fusion gene was negative. (C) One year after initiating imatinib therapy, the FIP1L1/PDGFRA fusion gene was also negative.
positive FDG uptake in multiple enlarged lymph nodes throughout body and in the red bone marrow. Because the FDG-PET findings strongly suggested malignant lymphoma, we performed a lymph-node biopsy of the neck. Microscopy revealed restiform hyperplasia of the capillary vessels, and small lymphoma cells with clear nucleoli were arranged around the capillaries (Fig. 4A). Lymphoma cells were immunohistochemically positive for CD3 (Fig. 4B), CD4, and CD10. These cells were also focally positive for CD21, and negative for CD20 and Epstein–Barr virus-encoded small nuclear RNA. The TCR gene rearrangement was positive based on Western blot analysis, and the FIP1L1/PDGFRA fusion gene was positive (86%) based on FISH analysis (Fig. 4C). From these findings, the patient was diagnosed with FIP1L1/PDGFRA-positive angioimmunoblastic T-cell lymphoma (AITL). All these findings suggested that the FIP1L1/PDGFRA fusion gene was involved in both hyper-eosinophilia in the peripheral blood and the development of AITL. From these findings, the clinical entity fell into the WHO 2016 category of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2.

After lymph-node biopsy, corticosteroid (prednisolone) (0.5 mg/kg/day) was administered but was ineffective. After imatinib initiation (100 mg/day), the patient’s symptoms, hyper-eosinophilia, and lymphadenopathy rapidly improved (Fig. 5) without any adverse events. Three months after imatinib initiation, FDG-PET revealed complete remission (CR) of AITL (Fig. 3B). A further 3 months later, the FIP1L1/PDGFRA fusion gene was negative based on FISH analysis in the peripheral blood (Fig. 1B). FDG-PET (Fig. 3C) and FISH analysis of the peripheral blood (Fig. 1C) after 1 year revealed CR of both HES and AITL, suggesting the successful treatment of HES and AITL by imatinib.

3. Methods
This study was approved by the ethics committee of Asahikawa Medical University (approval number 15208), and informed consent was obtained from the patient.

Peripheral blood and neck lymph nodes were processed by Carnoy’s fixation, and FISH analysis was performed using a FIP1L1/PDGFRA probe (Vysis LSI 4q12 Tricolor, Rearrange-ment Probe; Abbott Japan, Tokyo, Japan). FISH analysis of the bone-marrow smear was performed using the FIP1L1/PDGFRA probe. One hundred cells were examined for each analysis and the number of cells that were positive for the FIP1L1/PDGFRA fusion gene was counted.

4. Discussion
HES encompasses a group of rare disorders characterized by the presence of marked peripheral blood eosinophilia, tissue eosinophilia, or both, resulting in organ damage attributable to the eosinophilia. Blood HE should be defined as absolute eosinophil count in peripheral blood of >1.5 × 10^9/L observed on at least 2 examinations. Tissue HE should be defined...
by the following findings: (1) eosinophil in the bone marrow exceeds 20% of all nucleated cells, (2) infiltration of eosinophils in the tissue is extensively increased confirmed by the experienced pathologist, and/or (3) the observation of remarkable extracellular deposition of eosinophil granule-derived protein in the tissue. HES can be diagnosed if patients have organ damage attributable to tissue HE, with the exclusion of other reasons for organ damage, in addition to fulfilling the criteria for blood HE.

A previous report classified HES into 6 clinical variants according to the clinical course and laboratory findings: myeloproliferative HES (M-HES), lymphocytic variant HES (L-HES), overlap HES (which involves a single organ in addition to eosinophilia), associated HES (which has eosinophilia as a secondary phenomenon), familial HES, and idiopathic HES (which cannot be classified into the above categories). M-HES and L-HES were classified according to the cellular origin. M-HES is characterized by dysplastic eosinophils, circulating myeloid precursors, anemia, thrombocytopenia, splenomegaly, elevated serum vitamin B12 and/or tryptase levels, and atypical mast cells. In addition, M-HES often progresses to CEL or acute myeloid leukemia. The \textit{FIP1L1/PDGFR}A fusion gene has been reported in a few cases of M-HES. This gene encodes an active tyrosine kinase that drives clonal eosinophil proliferation, and results from a microdeletion on chromosome 4q12. This fusion gene is often detected in HES or CEL but very rarely in malignant lymphoma. Imatinib, a tyrosine kinase inhibitor, is reported to be very effective in \textit{FIP1L1/PDGFR}A-positive HES or CEL. By contrast, L-HES is reported to exhibit clones of an aberrant lymphocyte population producing cytokines (IL-5 and/or IL-3), which are the driving force of eosinophilia. L-HES is characterized by a high prevalence of skin and soft tissue manifestations, elevated serum IgE, and thymus and activation-regulated chemokine levels, and progresses to lymphoma or
leukemia.[11] The current patient had characteristics of both M-HES (positive for the FIP1L1/PDGFRα fusion gene, anemia, splenomegaly, and elevated serum vitamin B12 levels) and L-HES (progression toAITL), both of which responded well to imatinib. These findings suggest that the tumor cells have developed the FIP1L1/PDGFRα fusion gene at the earlier stage of hematopoietic progenitor cell development than in other cases of HES. In fact, previous reports have suggested that the FIP1L1/PDGFRα fusion gene mutation arises from pluripotent hematopoietic progenitor cells that may give rise to many different lineages, including eosinophils, mast cells, T-cells, B-cells, and others.[8–10] In the current case, the FIP1L1/PDGFRα fusion gene was detected in myeloid cells and lymphoid cells that developed tumorigenic transformation, but it might have also developed in cells of another lineage. Therefore, we should carefully observe whether cells of another lineage, in addition to eosinophil and lymphoid cells, develop tumorigenic transformation.

So far, 9 cases of lymphoma with HES have been reported (Table 2).[8–13] Among which, this patient is the first case of lymphoma and HES with FIP1L1/PDGFRα fusion gene involvement. In addition, 2 previous reports have demonstrated the effectiveness of imatinib in treating FIP1L1/PDGFRα-positive lymphoma,[8,11] but those patients did not have eosinophilia. The most striking point in this case is that the FIP1L1/PDGFRα fusion gene was detected both in the peripheral blood and in the lymph nodes, strongly suggesting that FIP1L1/PDGFRα plays a key role in the pathogenesis of both HES and AITL. Imatinib alone induced CR of not only the HES but also the lymphoma in the current clinical case, which may further support the above speculation.

5. Conclusion

We have presented a rare case of AITL and HES that were both positive for the FIP1L1/PDGFRα fusion gene. In the current case, the FIP1L1/PDGFRα fusion gene was considered to cause neoplastic changes not only in myeloid cells but also in lymphoid cells. We therefore speculate that these tumor cells developed the gene at an earlier stage of hematopoietic progenitor cell development compared with other cases of HES.

Table 2
Past cases of lymphoma with HES[8–13]
case No age/sex pathology of lymphoma complication of HES FIP1L1-PDGFRα fusion gene treatment outcome year
1 64 / M LyP→T cell lymphoma heart NA PUA, PSL, HU, IFN-α, CHOP PR 2000[9]
2 25 / M AITL heart, CNS NA CHOP, HD-AraC death 2001[10]
3 43 / F PTCL none NA CHOP, ESHAP death 2007[11]
4 35 / M PTCL none negative PSL, IFN-α, PUA CR 2006[12]
5 48 / M mycosis fungoides heart NA PSL, IFN-α, PUA CR 2007[12]
6 83 / F DBCL vasculitis negative PSL, IFN-α, PUA CR 2007[12]
7 60 / F PTCL eosinophilic pneumonia negative CHOP, THP-CDP death 2011[14]
8 65 / M PTCL none negative CHOP, Imatinib, meperazine, IFN-α PR 2013[15]
9 30’s / M PTCL none positive PSL, Imatinib CR current case

AITL = angioimmunoblastic T-cell lymphoma, AITCL = anaplastic T-cell lymphoma, CHASE = cyclophosphamide + high-dose cytarabine + daunorubicin + vincristine + prednisone, CNS = central nervous system, CR = complete remission, CsA = cyclosporine, ESHAP = etoposide + methylprednisolone + cisplatin + cytarabine, HD-AraC = high-dose cytarabine, HD-MTX = high-dose methotrexate, HES = hypereosinophilic syndrome, HU = hydroxyurea, IFN-α = interferon-α, IMVP-16 = ifosfamide + methotrexate + etoposide, LyP = lymphomatoid papulosis, NA = not available, PR = partial remission, PSL = prednisolone, PTCL = peripheral T-cell lymphoma, PUA = propranolol ultralow A, THP-CDP = cyclophosphamide + pirarubicin + vincristine + prednisolone.

References
[1] Klion AD. How I treat hypereosinophilic syndromes. Blood 2015;126: 1069–77.
[2] Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012;130:607–12.
[3] Simon HU, Rothenberg ME, Bochner BS, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010;126:45–9.
[4] Elder D, Baim B. Diagnosis and treatment of hypereosinophilic syndromes. Curr Opin Hematol 2007;14:37–42.
[5] Laimer D, Dolznig H, Kollmann K, et al. PDGFRα blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nature Medicine 2012;18:1699–704.
[6] Turner SD. Inimitable Imatinib: the range of targeted tumours expands to lymphomas. The Lancet 2012;379:777–8.
[7] Turner SD. Imatinib: the range of targeted tumours expands to lymphomas. The Lancet 2012;379:777–8.
[8] Granel B, Serratrice J, Swiadr L, et al. Lymphomatoid papulosis: a case report and review. Leuk Lymphoma 2006;47:357–7.
[9] Aractingi S, Bachmeyer C, Pautier P, et al. Necrotic cutaneous lesions induced by hypereosinophilic syndrome secondary to a T-cell lymphoma. J Am Acad Dermatol 2002;46:S133–6.
[10] Choi W, Park YH, Paik KH, et al. Peripheral T-cell lymphoma: unspeciated (PTCL-u) presenting with hypereosinophilic syndrome and pleural effusion. Korean J Intern Med 2006;21:57–61.
[11] Beyazit Y, Haznedaroğlu IC, Aksoy S, et al. Changing clinical manifestations of T-peripheral lymphoma: from hypereosinophilic syndrome to questionable Kimura’s disease resulting in parotid mass. Leuk Lymphoma 2006;47:537–60.
[12] Lee CH, Mamela KJ, Vonderheid EC. Erythrodermic cutaneous T-cell lymphoma with hypereosinophilic syndrome: treatment with interferon alfa and extracorporeal photopheresis. Int J Dermatol 2007;46: 1198–204.
[13] Nozawa K, Kaneko H, Itoh T, et al. Synchronous malignant B-cell lymphoma and gastric tubular adenocarcinoma associated with paraneoplastic cutaneous vasculitis: hypereosinophilic syndrome with mixed cryoglobulinemia is an important sign of paraneoplastic syndrome. Rare Tumors 2009;1:128–31.
[14] Kunimasa K, Arita M, Arai Y, et al. Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) in a patient with hypereosinophilic syndrome showing multiple nodules on chest computed tomography. Intern Med 2011;50:2417–21.
[15] d’Ellée JM, Parrens M, Mercie P, et al. Hypereosinophilic syndrome—lymphocytic variant transforming into peripheral T-cell lymphoma with severe oral manifestations. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116:e185–90.

www.md-journal.com